Pharsight

Drugs that contain Saxagliptin Hydrochloride

1. Onglyza patents expiration

ONGLYZA's oppositions filed in EPO
ONGLYZA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(8 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6395767 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Feb, 2021

(3 years ago)

US7951400 ASTRAZENECA AB Coated tablet formulation and method
Nov, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-134) May 24, 2016
M(M-175) Apr 05, 2019
M(M-198) Feb 27, 2020
New Chemical Entity Exclusivity(NCE) Jul 31, 2014
M(M-108) Dec 16, 2014

NCE-1 date: 31 July, 2013

Market Authorisation Date: 31 July, 2009

Treatment: Method for treating type ii diabetes by administering saxagliptin; Method for treating type ii diabetes mellitus by administering saxagliptin alone or in combination with insulin, metformin, a thiazol...

Dosage: TABLET;ORAL

How can I launch a generic of ONGLYZA before it's drug patent expiration?
More Information on Dosage

ONGLYZA family patents

Family Patents